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SUMMARY
It is often difficult to detect a malignant tumor and assess the presence of
metastases. Therefore it is important to have a non-invasive test than can
visualize these lesions
ruCo-bleomycin (lz6o-Ot-, is a radiopharmaceutical that is used for these
purposes especially in patients with lung cancer. The aims of the present
study were to determine the value of ,7Co-blm scintigraphy as it is used in
clinical practice and to improve the radiopharmaceutical and detection
procedure. This work is a sequel to the work of Rasker (251).
The properties of the ideal tumor imaging radiopharmaceutical are out-
lined in cbapter í. This hypothetical agent should accumulate in malignant
tumors but not in other lesions and not in normal tissues. It should have few
side effects, a short half-life, emit radiation with a suitable energy for in vivo
detection and be generally available for a reasonable price.
The specific and non-specific mechanisms by which tumor imaging radio-
pharmaceuticals are accumulated in tumor tissue are discussed.
Tumor imaging radiopharmaceuticals canbe arcanged roughly into three
major groups: metabolite related agents, immunological substances and
non-specific compounds. Many radiopharmaceuticals that have been used ar
one time or another are briefly discussed. In the section on metabolite related
agents, special attention is paid to bleomycin (blm) and tTCo-blm. The group
of immunological substances consists of radiolabeled antibodies against
antigens that are presenr in tumors. 67Ga-citrate is the best known tumor
imaging agent among the non-specific compounds. It is widely used in
nucleas-medicine. Its history, indications and disadvanrages are discussed.
In cbapter 2, a brief. review is presented on lung cancer epidemiology,
pathology, etiology, prevention, clinical symproms and signs, therapy and
prognosis. New developments in this field are reviewed. Various techniques
to establish the diagnosis of lung cancer and to detect metastases are dis-
cussed more extensively. The importance of assessing the correct stage of
the disease is stressed.
The labeling procedure of blm with tTCo and the value of tTCo-blm in the
detection of primary lung cancer are described in chapter 3. Over a5 year
period, tTCo-blm scintigraphy for tumor detection was performed in our
r13
Iinstitute with a large field of view gamma camera. The scintigrams of 287
well documented patients with lung cancer' other types of neoplasm, non-
malignant lesions or no abnormality in the lung were reviewed. A sensitivity
of g6% was found for the detection of lung cancer. False negative and equi-
vocal scintigrams were seen in Patients with small lesions'
Nineteen parients proved to have anorher type of malignant tumor in the
lung, mostly merasrases from rumors elsewhere in the body. of these lesions'
l3 6S%) were visual ized. 57co-blm scint igraphy cannot dif ferentiate
between lung cancer and other malignancies'
It is important to determine the value of tTco-blm scintigraphy in patients
in whom a preoperative parhological diagnosis cannot be obtained by reaso-
nable means. In such a subgroup of 194 cases, sensit ivi ty was957o and speci-
Ircltv ó / u/o.
correlation between tumor size and tumor-to-non-tumor ratio (TNT-
rario) was established for squamous cell carcinoma, adenocarcinoma and
small cell carcinoma. Adenocarcinomas were smaller and showed lower
TNT-ratios than other histological types. A correlation between histological
differentiation and TNT-ratio could nor be established for squamous cell
carcinoma.
Forty of 46 scintigraphic studies in patients with a non-malignant lesion
or no abnormality in the lung were rrue negative. This leads to a specificity
or 877o. tTCo-blm scintigraphy results in 112 Patients with various non-
malignant lesions in rhe lung were collected from the literature, including
the present results. overall specificity wasSl(y'o. Most false positive studies
were seen in patients with active tuberculosis and unspecified pneumonia. It
is concluded that tTCo-blm scintigraphy is helpful in patients suspected of
having lung cancer in whom a pfeoperarive pathological diagnosis cannot be
obtained.
In chapter 4, the vailue of 57Co-blm scintigraphy for staging lung cancer
was investigated.inlT4 patients. In the detection of lymph node metastases
in the hilus and mediastinum' the sensitivity was J47o and the specificity
98Vo. tlCo-blm scintigraphy proved to be more reliable than chest radio-
graphy and roentgen tomograPhY.
Distant merasrases were sought in 44 patients. False positive or false
negarive results were nor found in this group. The tTco-blm brain scinti-
grams were of particularly good quality.




































































of metastases in the hilus and mediastinum is discussed on the basis of data
reported in the literature.
It is concluded that ,7Co-blm scintigraphy has a limited potential to detect
lymph node metastases in the hilus and mediastinum. llowever, a positive
scintigram is highly suggestive of the presence of metastatic disease. tTCo-
blm scintigraphy is a reliable technique to visualize brain metastases.
Staging of lung cancer patients in our hospital routinely includes tTCo-blm
scintigraphy in addition to conventional roentgen tomography. Medias-
tinoscopy is rarely done nowadays. Síhen tTCo-blm scintigraphy shows
extensive mediastinal involvement, surgery is not performed. Iíhen scinti-
graphy indicates limited hilar or mediastinal involvement, extensive surgery
including removal of the affected lymph nodes is considered. \íhen scinti-
graphy does not show met4stases, radical resection is carried out when
otherwise no contra-indications are present. In a number of patients in this
latter group, lymph node metastases will be found during surgery, but this is
always limited and rarely modifies the intended radical resection.
67Ga-citrate is a widely used radiopharmaceurical for the derection and
staging of lung cancer. A comparative study of 67Ga-citrare and tTCo-blm in
63 patients with proved lung cancer is described in cbapter 5.67Ga-citrate
showed the primary tumor in 34 patients (54%) and tTCo-blm in 58 (92%)
(p(0.05). The mean difference in TNT-ratios in individual patients was
significant in favor of tTCo-blm scintigraphy.
Proven metastases in the lung hilus and mediastinum were visualized
with 67Ga-citrate in only 8 out of 18 patients (45%) and with tTCo-blm in 16
(89%) (p(0.05). These results indicate that tTCo-blm scintigraphy is more
suitable for detecting and staging lung cancer than is 67Ga-citrate scinti-
graphy.
Blm, as it is commercially available, is a mixrure of various blm fractions.
Blm-mixture and the isolated fractions blm-A2. blm-Á5 and blm-B2 were
labeled with 57Co.
In chapter 6 the tumor seeking properries of these compàtrnds were
investigated. Biodistribution was determined in rars bearing \Talker carci-
noma, Yoshida sarcoma or rhabdomyosarcoma. Tissue concenrrarions of
tTCo-blm-mixture and tTCo-blm-A2 were generally similar. tTCo-blm-B2
showed a higher uptake in most tissues. Tumor-to-tissue rarios of these
three compounds were similar. tTCo-blm-A5 showed clearly inferior tumor
1 1 5
seeking properties. It is concluded that, in the experimental models that we
used, the investigated labeled blm fractions are not superior to tTCo-blm-
mixture for tumor detection.
;7Co-blm, as it is administered to patients, contains a considerable amount
of unlabeled blm. To limit side effects to the patients and to reduce costs, the
quantity of blm should be as low as possible. Reduction of the amount of blm
however should not result in an increase in the percentage of free 57Co2+
ions, since these are largely retained in the body and considerably add to the
radiation dose. Variations in the ratio of tTCo and blm in the labeling proce-
dure were investigated in chapter 7. A fixed amount of 7.4MBq (0.2 mCi)
tTCo was added to successively 21.0,9.0,0.9,0.09 and0.009 mg (weight) blm
in the preparation of tTCo-blm.
Iíhen the smallest amount of blm was used, the labeling yielded a percen-
tage of t7co2+ that was far too large. The percentage of free t7co2+ in the
orher four compounds was acceptable, being less than 3% of the total
activity.
Biodistribution of radioactivity of all five compounds was investigated in
rats bearing Yoshida sarcoma. Of the compound with excess stco2+, radio-
activity uptake in the rumor was similar to uptake of the other compounds,
but uptake in normal tissues was clearly higher. This resulted in inferior
tumor-to-tissue ratios. Tissue concentrations and tumor-to-tissue ratios of
the other four compounds were similar.
It is concluded that, compared to the quantity traditionally used, the
amount of blm in the labeling procedure can be reduced without increase in
the percentage of free t7co2+ and without reduction in the tumor seeking
properties in rats with Yoshida sarcoma. On the basis of these results, the
quantity of blm administered to patients for tTCo-blm scintigraphy (1.5 mg
weight) will be reduced.
The long half-life of tTCo (272 d:ays) ius discoo.rged the widespread
acceptance of tTCo-blm. Because a major fraction of the radioactivity is
quickly excreted by the kidneys, the contaminated urine should be collected
and stored to prevent environmental contamination. Since the labeling of
blm with other radionuclides did not lead to a useful tumor imagingagett,
we investigated ttCo (hàlf-life 17.5 hours) as potential label. The results are
described io chapter 8.
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: cyclotron of the
University of Groningen. After purification, tsCo is attached to blm with the
procedure as described for tTCo in chapter 3. Fifty patients with proven lung
cancer were investigated with t tCo-blm. A dose of 37 MBq (1.0 mCi) was
administered intravenously. The results were compared with tTCo-blm
scintigraphy. Since ttCo is a positron emitting radionuclide, a positron
camera was used for imaging. The characteristics of rhis device are briefly
described. Tomographic images were obtained and proved ro be of good
quali ty. Sensit ivi ty in the detection of primary tumors was967o for rtCo-blm
positron imaging, whereas for tTCo-blm imaging this was 98%. TNT-ratios
of ttCo-blm scintigraphy were significantly lower than those of tTCo-blm
scintigraphy. TNT-ratios obtained with t5Co-blm after compurerized
filtering were significantly higher than those obtained with tTCo-blm.
However, the filtered images were not always easy to evaluate.
ttCo-blm and tTCo-blm were equally sensitive in the detection of lymph
node metastases in the hilus and mediastinum. One false positive ttCo-blm
study was found versus no false positive tTCo-blm studies. In all six patienrs
with a brain metastasis, this was clearlv demonstrated on the ttCo-blm
tomograms.
Advantages and disadvantages of ttCo-blm positron scintigraphy are
discussed. It is concluded that the results are good enough to replace rTCo-
blm scintigraphy. The more refined positron imaging equipment that has
recently become available will probably improve the results in the near
future.
ln chapter 9, organ radiation doses and somatically effective total body
dose to the adult patient from a study with tTCo-blm or , tCo-blm were
calculated using the MIRD (Medical Internal Radiation Dose) scheme. The
radioactivity is mainly concentrated in bladder, kidneys and liver. It is
assumed that the rest of the radioactivity is distributed homogeneously
throughout the remainder of the body.
Residence times - cumulated activities per unit of injected amounr of
radioactivity - for these three organs and the remainder of the body were
derived from tTCo-blm clearance measurements in patients. The radiat ion
dose was calculated for the gonads and all organs that contribute to the
somatically effective total body dose. The somatically effective total body
dose is 70 + 8 pGy /MBq Q.26 + 0.03 rad/ mCi) for :7Co-bl m and 170 * 24
pGylMBq (0.63 L 0.09 radlmCi) for I tCo-blm (* t  s.d.).  The inf luenceof





radiation dose are discussed. The calculated somatically effective total body
dose of both radiopharmaceuticals is comparable to rhat of other scinti-
graphic studies.
New developments in tumor imaging are describedín chapter 10. Tesring
new blm fractions might lead ro a componenr rhat has better tumor seeking
properties. Research in the labeling of a ligaod of non-radioactive cobalt and
blm with radionuclides that emit a suitable gamma energy might lead to a
compound that carries no risk of environmental contamination and that can
generally be used for imaging with a gamma camera.
In the near future, the introduction of a rotatable double headed gamma
camera, adapted for positron imaging, offers the opportunity to quantify the
amount of radioactiviry in a certain aÍea in the body. This feature might
enable us to guide tumor therapy more accurarely.
Two main directions can be discerned in the search for more specific
tumor imaging agents: metabolite related agents (such as amino acids
labeled with the posrtron emitt ing 
"C, 
trN, 
"O) and (monoclonal) anri-
bodies against tumor specific anrigens.
Nude mice bearing human rumors might make it possible ro test rumor
imaging radiopharmaceuricals in animals and obtain resulrs rhat are highly
predictive for human beings.
Síhen a truly specific tumor imagin g agent is found, we should consider
converting this compound into a therapeuric agenr by labeling it with a
radionuclide with suitable physical characteristics.
Nuclear magnetic resonance (NMR) is another new clinical imaging tech-
nique. Its potential in tumor imaging is briefly discussed.
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